The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines. by Morandi, Andrea et al.
The Colony-Stimulating Factor-1 (CSF-1) Receptor
Sustains ERK1/2 Activation and Proliferation in Breast
Cancer Cell Lines
Andrea Morandi¤a, Valentina Barbetti, Maria Riverso¤b, Persio Dello Sbarba*, Elisabetta Rovida*
Dipartimento di Patologia e Oncologia Sperimentali, Universita` degli Studi di Firenze, and Istituto Toscano Tumori, Firenze, Italy
Abstract
Breast cancer is the second leading cause of cancer-related deaths in western countries. Colony-Stimulating Factor-1 (CSF-1)
and its receptor (CSF-1R) regulate macrophage and osteoclast production, trophoblast implantation and mammary gland
development. The expression of CSF-1R and/or CSF-1 strongly correlates with poor prognosis in several human epithelial
tumors, including breast carcinomas. We demonstrate that CSF-1 and CSF-1R are expressed, although at different levels, in
16/17 breast cancer cell lines tested with no differences among molecular subtypes. The role of CSF-1/CSF-1R in the
proliferation of breast cancer cells was then studied in MDAMB468 and SKBR3 cells belonging to different subtypes. CSF-1
administration induced ERK1/2 phosphorylation and enhanced cell proliferation in both cell lines. Furthermore, the
inhibition of CSF-1/CSF-1R signaling, by CSF-1R siRNA or imatinib treatment, impaired CSF-1 induced ERK1/2 activation and
cell proliferation. We also demonstrate that c-Jun, cyclin D1 and c-Myc, known for their involvement in cell proliferation, are
downstream CSF-1R in breast cancer cells. The presence of a proliferative CSF-1/CSF-1R autocrine loop involving ERK1/2 was
also found. The wide expression of the CSF-1/CSF-1R pair across breast cancer cell subtypes supports CSF-1/CSF-1R
targeting in breast cancer therapy.
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Introduction
The c-fms proto-oncogene encodes the only known receptor
(CSF-1R) for Colony Stimulating Factor 1 (CSF-1 or M-CSF)
[1,2]. CSF-1R is a class III transmembrane tyrosine kinase
receptor and its ligand CSF-1 has secreted glycoprotein, secreted
proteoglycan and membrane-bound isoforms [3,4]. The CSF-1/
CSF-1R pair has essential physiological functions in the generation
of osteoclasts and macrophages [4] and, via its action on
macrophages and other CSF-1R-expressing cells, in female and
male fertility [5,6]. Activation of CSF-1R by its ligand triggers a
series of rapid events, including receptor dimerization and tyrosine
phosphorylation of its intracellular domain. Phosphorylation at
particular CSF-1R tyrosines creates binding sites for a variety of
cytoplasmic proteins that activate signal transduction pathways
including that of ERK1/2 and PI3K [7].
CSF-1 and CSF-1R are expressed in normal breast tissue
during puberty, pregnancy and lactation. However, the expres-
sion of CSF-1R and/or CSF-1 has been documented in several
human cancers, including carcinomas of breast, female repro-
ductive tract, prostate and kidney [8–15]. Data reported in
literature for solid tumors indicate that the oncogenic potential of
CSF-1/CSF-1R is due to the co-expression of this growth factor/
receptor pair, rather than CSF-1R overexpression or mutations
activating CSF-1R independently of ligand [6]. This is supported
by the fact that the expression of normal c-fms into CSF-1-
expressing non-transformed fibroblasts and epithelial cells can be
sufficient to induce a fully transformed phenotype [16,17]. In this
respect, activation of CSF-1R by its ligand is likely to occur in
tumor cells in which CSF-1R and CSF-1 are co-expressed (i.e.
autocrine activation), or when CSF-1R is stimulated by CSF-1
released by cancer associated fibroblasts (i.e. paracrine activa-
tion). Consistent with this, in breast cancer patients, the
expression of both CSF-1 and its receptor in neoplastic epithelial
cells strongly correlates with poor prognosis and is predictive of
ipsilateral recurrence [18–20]. In addition, the presence of tumor
associated macrophages in breast tumors also correlates with
poor prognosis [19,21] and, in mouse models, CSF-1 promotes
metastasis [22], stimulates angiogenesis [23,24] and is involved in
a paracrine loop with EGF to promote tumor cell invasion [25].
While previous studies indicated that CSF-1R and CSF-1 are
expressed in breast cancer cell lines and tumors and demonstrat-
ed the relevance of CSF-1/CSF-1R signaling in the invasiveness
of breast cancer cells [26–31], few studies have focused on the
biological role of CSF-1/CSF-1R signaling in the proliferation of
breast cancer cells.
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Targeting receptor tyrosine kinases with kinase inhibitors (e.g.
imatinib, dasatinib or nilotinib) has recently opened a new era in
the treatment of hematologic malignancies and solid tumors such
as gastrointestinal stromal tumors [32,33]. These drugs are
effective on CSF-1R [34,35] and other CSF-1R-specific inhibitors
have been developed [36–38]. More importantly, several drugs
targeting CSF-1 and CSF-1R are currently in Phase I/II trial
(www.clinicaltrials.org). Elucidation of the involvement of CSF-1R
in breast cancer cell proliferation would strengthen the rationale of
CSF-1R targeting in CSF-1R expressing cancers.
In this work, we characterized the role of CSF-1R in the
proliferation of breast cancer cells and found that CSF-1R is
widely expressed in breast cancer cell lines at both mRNA and
protein levels. Interfering with the CSF-1/CSF-1R signaling
pathway, either by CSF-1R inhibition or by inhibition of autocrine
CSF-1, impaired MDAMB468 and SKBR3 cell proliferation. In
addition, exposure to ectopic CSF-1 stimulated MDAMB468 and
SKBR3 growth. We found ERK1/2, c-Jun, cyclin D1 and c-Myc,
known for their involvement in cell proliferation, to be
downstream CSF-1R in breast cancer cells. The wide expression
of CSF-1/CSF-1R pair across breast cancer cell subtypes supports
CSF-1/CSF-1R targeting in breast cancer therapy.
Materials and Methods
Cells and cell culture
NIH/3T3 murine fibroblasts expressing ectopic human CSF-
1R (kind gift of MF Roussel, St. Jude Children’s Research
Hospital, Memphis, TN, USA) [39] and HepG2 human
hepatoblastoma cells (www.lgcstandards-atcc.org) periodically
tested in our laboratory by western blotting for the presence of
EGFR protein) were cultured in DMEM, while human chronic
myeloid leukemia K562 cells (www.lgcstandards-atcc.org); period-
ically tested in our laboratory by western blotting or Q-PCR for
the expression of BCR/Abl) in RPMI, supplemented with 4 mM
glutamine and 10% fetal bovine serum (FBS). Human primary
macrophages were obtained after informed consent as previously
described [40]. The breast cancer cell lines (MCF7, T47D,
MDAMB175VII, ZR751, 734B, MDAMB361, BT474, SKBR3,
MDAMB453, HCC1954, MDAMB468, BT20, SUM149PT,
HCC1500, MDAMB231) and MCF10A and MCF12A cells (two
immortal, non transformed cell lines showing basal B molecular
pattern) [41,42] were a kind gift of Dr MG Daidone and Dr E
Tagliabue, Istituto Nazionale Tumori, Milano, Italy; Dr D
Lerouge, Institut Gustave-Roussy, Villejuif, France; Prof CM
Isacke, Institute of Cancer Research, London, UK. Laboratories
of origin have tested all cell lines by microsatellite analysis or
microarray. However, cells have been tested upon arrival and
periodically in our lab by western blotting for HER2, EGFR and
by PCR for estrogen receptor expression. Cells were cultured as
previously described [41]. Cells were incubated in the presence or
the absence of 100 mg/ml streptomycin and 100 I.U. penicillin, at
37uC in humidified atmosphere containing 5% CO2.
Analysis of Gene Expression and cGH Datasets
Data were obtained mapping CSF-1 and CSF-1R gene symbols
to GSE2603 (probes 2078082_at and 203104_at) [43], NKI
(probes NM_000757 and NM_000971) [44] and Neve (probes
2078082_at and 203104_at) [41] datasets. Cell lines molecular
subtypes were reported as classified by the authors in the Neve
dataset [41]. Breast cancer subtypes of tumor samples were
predicted using centroid Spearman correlation to the PAM50
classifier in NKI and GSE2603 datasets. The PAM50 gene
expression predictor classifies breast cancers into molecular
intrinsic subtypes (Luminal A, Luminal B, HER2-enriched,
Basal-like) and provides a risk of recurrence (ROR) score based
on the similarity of an individual sample to prototypic subtypes
[45]. GSE2603 data were GCRMA normalized, NKI data were
mean centered normalized and the Neve data were RMA
normalized as reported by the authors in their studies using the
ROCK database [46]. The CGH array data for CSF-1R and
CSF-1 were obtained from Neve [41] and Fridlyand [47] (RP1-
141L3 and CTD-2050A15). Statistical analysis was performed
using Prism software (GraphPad Software, La Jolla, CA, USA).
Means of the normalized data of each subtype were compared
using one-way ANOVA and the Bonferroni test. Differences were
considered statistically significant when p,0.05. We did not
submit our research to the local ethical committee nor did we
obtain informed consent for the use of tumor explants because our
analyses were performed on publicly available datasets (see below).
Total cell lysates
Culture plates were placed on ice, cell monolayers rapidly
washed 3 times with ice-cold PBS containing 100 mM orthova-
nadate and cells lysed by scraping in Laemmli buffer (Tris/HCl
62.5 mM, pH 6.8, 10% glycerol, 0.005% blue bromophenol, 2%
SDS) and incubating at 95uC for 10 minutes in the presence of
100 mM 2-mercaptoethanol. Lysates were then clarified by
centrifugation (20000 g, 10 minutes, RT).
Western Blotting and Immunoblotting
30–60 mg of total proteins was separated by SDS-PAGE in 9–
15% polyacrylamide gel and transferred onto PVDF membranes
(Millipore) by electroblotting. Membranes were incubated (1 hour,
RT) in Odyssey Blocking Buffer diluted 1:1 with PBS, and then in
the same buffer containing 0.1% Tween-20 and the primary
antibody (16–18 hours, 4uC). After extensive washing with PBS/
0.1% Tween-20, membranes were incubated in Odyssey Blocking
Buffer diluted 1:1 with PBS containing IRDyeH800CW- or
IRDyeH680-conjugated secondary antibody (1 hour, 4uC). Bands
were visualized by infrared imaging (Licor, Odissey) and images
recorded as TIFF files for quantification with Adobe Photoshop
software. Rabbit a-phospho-T202/Y204-ERK1/2 (Cell Signaling,
# 9101); rabbit a-ERK1 (Santa Cruz, sc-93); rabbit polyclonal a-
CSF-1R C-20 (Santa Cruz; sc-692); goat a-CSF-1 antibody N-16
(Santa Cruz, sc-1324); a-phospho-723-CSF-1R (Cell Signaling, #
3151); mouse a-vinculin (sigma; V9131); rabbit a-phospho-S63/
73-c-Jun (Santa Cruz; sc16312); mouse monoclonal a-cyclin D1
(Santa Cruz, sc-8396); mouse monoclonal a-myc (Santa Cruz, sc-
8396).
Flow cytometry
Cells were detached by incubation in PBS containing 0.2%
EDTA (pH 7.2), washed with PBS, pelleted and incubated in
20 ml of an anti-CSF-1R antibody (24A4, PE-conjugated; sc-02PE;
Santa Cruz Biotechnology) [48] or isotype control antibody
(IgG2b, sc-2873, Santa Cruz Biotechnology) for 45 minutes in the
dark. After two washes with PBS followed by a 5 minutes
centrifugation, cells were resuspended in 500 ml PBS and analyzed
with a FACSCanto (Becton Dickinson). The percentage of positive
cells was calculated by subtracting values obtained with isotype
control antibody from those obtained with anti-CSF-1R antibody.
Enzyme-Linked ImmunoSorbent Assay
CSF-1 was measured by ELISA (RayBio ELISA KIT Human
MCSF), according to the manufacturer’s instructions. The
manufacturer claims that the minimum detectable dose of CSF-
CSF-1R Promotes Cell Growth in Breast Cancer Cells
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1 is typically less than 5 pg/ml (sensitivity of the methods).
Supernatants were collected at cell confluency from cultures in
complete medium. Each sample (100 ml) was assessed in duplicate.
CSF-1R silencing with siRNA and measurement of DNA
synthesis by [3H]thymidine uptake
Silencing was performed as previously described [40] with
100 nM SMART-pool siRNA for CSF-1R (NM_005211 mRNA,
Dharmacon, cat. No M-003109-03), 100 nM SMART-pool siRNA
for CSF-1 (NM_000757, Dharmacon, cat. No M-017514-00) or
100 nM siCONTROL non-targeting pool (Dharmacon, cat. n. D-
001206-13) following the manufacturer’s instructions. Transfection
efficiency was 90%, as assessed by cotransfection with Cy3-labelled
siGLO RISC-free siRNA (Dharmacon, cat. n. D-001600-01). One
day after transfection, cells were serum starved for 24 hours before
treatment with CSF-1 for 24 h. [3H]thymidine uptake analysis was
performed as previously described [40].
Measurement of DNA synthesis by bromodeoxyuridine
uptake and immunofluorescence
Cells were seeded onto glass coverslips in complete medium for
24 hours and then incubated in the absence of FBS for 24 hours
before being incubated in DMEM with or without 25 ng/ml CSF-1
or a 1:50 dilution of a goat a-CSF-1 blocking or pre-immune serum
[49] for further 24 hours. During the last 4 hours of incubation,
bromodeoxyuridine (BrdU) was added to the culture (final
concentration 10 nM) and then BrdU uptake was stopped by
incubating cells in 4% formaldehyde/PBS for 10 minutes at RT.
After washing in PBS, cells were incubated for 20 minutes with 2M
HCl and then 0.1 M Na2B4O7 was added. Cells were washed with
PBS and permeabilized by a 5 minute incubation in PBS containing
0.2% Triton X-100. After three washes in PBS cells were incubated
with 10% horse serum in PBS/1%BSA for 45 minutes and then
washed in PBS and incubated overnight at 4uC in a 1:250 dilution of
a mouse monoclonal a-BrdU antibody (Millipore, MAB3222) in
PBS/1%BSA, washed with PBS and incubated with a 1:800
dilution of an a-mouse Cy3-labelled secondary antibodies (Chemi-
con, AP192C). Cells were washed in PBS and incubated with 5 mg/
ml Hoechst 33258 (Sigma) nuclear dye in PBS for 10 minutes.
Following two washes in PBS, coverslips were mounted with propyl-
thiogallate on glass slides and cells observed with a Leica DC200
microscope. Pictures were taken from 6 different field/sample
(.600 cells were scored for each treatment) and the percentage of
cells undergoing DNA synthesis was calculated by the ratio of the
number of BrdU-positive cells to the total number of cells
determined by Hoechst 33258 staining. Incubation with secondary
antibody alone did not produce any significant fluorescence.
Measurement of cell number by Crystal Violet staining
Cells were seeded in 12 multi-well plates and incubated for
24 hours in complete medium before serum starvation for further
24 hours. Cells were then treated in serum-free medium with
imatinib (Gleevec, Glivec, Novartis, Basel, Switzerland) for
45 minutes and then with CSF-1 for further 48 hours. Cell were
then washed twice with PBS and incubated for 10 minutes at RT
with a Crystal Violet solution (0.5% Crystal violet, SIGMA, 30%
ethanol and 3% formaldehyde). After extensive water washing,
plates were allowed to dry and dye extracted by incubating with 1%
SDS. Densitometric measurement was then performed at 550 nm.
Quantitative Real-Time PCR (Q-PCR)
After total RNA extraction by TRIzol (Invitrogen) as specified
by the manufacturer, 1 mg of total RNA/sample was submitted to
reverse transcription with SuperScriptVILO-Reverse Transcrip-
tase (Invitrogen) for 10 minutes at 25uC, 1 hour at 42uC and
5 minutes at 85uC utilizing 50 pmol random hexameric primers.
The primers used were as follows: CSF-1R, C-term, for: 59-
CCTCGCTTCCAAGAATTGCA-39, rev: 59-CCCAATCTTG-
GCCACATGA-39 (amplicon size 60 bp, designed to span the
intron between exons 16 and 17); CSF-1R, N-term, for: 59-
GGAGGCTGCCCAGATCGT-39 rev: 59-GCGAGCTTGGTG-
TTGTTGTG-39 (amplicon size 60 bp, designed to span the
intron between exons 4 and 5); cyclin D1 (CCND1), for: 59-
GAGAGGAAGCGTGTGAGGCGGTAG-39, rev: 59-GGATG-
CTGGAGGTGCGAGGA-39; cyclin G1 (CCNG1), for: 59-CCA-
GCTGAATGCCCTGTTG-39, rev: 59-AGTCTCAAACCACA-
GACCTTTGG-39; cyclin H (CCNH), for: 59-GAGGAGCAG-
CTGGCAAGACT-39, rev: 59-ACGGCTTTGCATCTGAAT-
TTG-39; cyclin I (CCNI), for: 59-CATCTCAACATTTGGCA-
GTCCTT-39, rev: 59-GAAGTTGGTTGCAGGCCATAC-39;
rRNA 18S, for: 59-CGGCTACCACATCCAAGGAA-39, rev:
59-GCTGGAATTACCGCGGCT-39 (amplicon size 180 bp);
GAPDH, for: 59-AACAGCC TCAAGATCATCAGCAA-39,
rev: 59-CAGTCTGGGTGGCAGTGAT-39. CSF-1R mRNA
expression was assessed by Q-PCR (2 minutes 50uC, 5 minutes
95uC, 40 cycles at 95u C for 15 seconds and 60uC for 1 minute)
with the ABI Prism 7500 Sequence Detection System (Applied
Biosystem) using Power SYBRH Green PCR master mix (Applied
Biosystem). A melting curve analysis was performed to discrim-
inate between specific and non-specific PCR products. Alterna-
tively, amplified product size was verified by running in 3–4%
agarose gels. The housekeeping 18S rRNA and/or GAPDH genes
were used as internal references for normalization. The relative
expression of CSF-1R, with respect to SKBR3 cells chosen as
calibrator, was calculated by using a comparative threshold cycle
method and the formula 2(2DDCt) [50].
Analysis of StellARray Gene Expression
SKBR3 cells were transfected with the indicated siRNA and
cultured in complete medium for 72 hours. Cells were then lysed
and total RNA extracted. Gene expression analysis was performed
with Q-PCR Arrays (Human Cell Cycle Tox and Cancer 96
StellARrayTM qPCR array 00188263 Fast 96 Well, Lonza). A list
of these 96 genes is available online at http://array.lonza.com/
plate/00188263/. The housekeeping rRNA 18S gene was used as
internal reference for normalization. Fold change was calculated
as described above. Data reported (+SEM) were obtained from
four independent experiments.
Results
The expression of CSF-1R and/or CSF-1 in human breast
carcinomas has been documented in both cell lines and tumors
samples [8–10,12,15]. However, whether their expression is
restricted to one molecular subtype has not been studied. To
address this issue, we performed Q-PCR for CSF-1R mRNA
on 17 cell lines endowed with different molecular profiles and
referred to as luminal, basal A and basal B subtypes
(Figure 1A) [41,42,51,52]. These experiments indicated that
CSF1R is expressed, although at different levels, in all cell lines
tested.
The presence of cell surface CSF-1R protein was then verified
by flow cytometry (Figure 1B, S1A). All the cell lines tested, except
HCC1500, MCF10A and MCF12A, expressed appreciable cell
surface CSF-1R. However, MCF10A and MCF12A cells ex-
pressed high levels of CSF-1R mRNA. We hypothesized that these
differences are due to ligand-induced down-regulation of the
CSF-1R Promotes Cell Growth in Breast Cancer Cells
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receptor (see below). Furthermore, ectopic CSF-1 activates
ERK1/2 in these cells pointing to the presence of functional
CSF-1R. In contrast, HCC1500 cells express very low CSF-1R
mRNA levels and did not respond to CSF-1 as monitored by
activation of ERK1/2 (Figure S3), PI3K or ERK5 (not shown).
HCC1500 is, therefore, the only breast cancer cell line of the panel
analyzed that we consider CSF-1R negative. The analysis of mean
fluorescence intensity produced similar results (not shown). No
significant differences in cell surface CSF-1R expression among
subtypes were found by one-way ANOVA (not shown).
The cell lines were also tested for CSF-1 expression by
measurement of secreted CSF-1 (by ELISA and western blotting)
and of CSF-1 in cell lysates (by western blotting). CSF-1 was
detected in all the cell lines tested (Table 1). It is of note that we
were unable to detect CSF-1 in SKBR3 supernatants by ELISA, a
finding that is at variance with previous reports [53]. The
detection of CSF-1 in total cell lysates of SKBR3 indicates that
these cells, which are known to express CSF-1 [15], may express
membrane-bound CSF-1.
The data reported in Figure 1 and Table 1 indicated that all the
cell lines tested express CSF-1 and that 16/17 express CSF-1R. In
addition, we performed in silico analysis on publicly available gene
expression profiling datasets (Figure 2) [41,43,44]. This analysis
indicated that the mean expression of CSF1 and CSF1R genes did
not vary significantly (assessed by One-way ANOVA analysis)
among breast cancer subtypes in either cell lines or in tumors
samples. Moreover, in silico analysis of comparative genomic
hybridization datasets relative to 49 breast cancer cell lines [41]
and 67 primary tumors [47] indicated the absence of CSF-1R or
CSF-1 gene amplifications (Figure S2).
Figure 1. Expression of CSF-1R in breast cancer cell lines. (A) Routinely cultured cells were lysed and total RNA extracted. Q-PCR was
performed using two different sets of primers (C-terminus, light gray; N-terminus, dark grey). The 18S rRNA was used for normalization and SKBR3
were chosen as calibrator. Data represent the mean (6 SD) of three independent experiments. Asterisks indicate the HER2-overexpressing cell lines.
(B) Routinely cultured cells were processed and subjected to flow cytometry with a rat monoclonal anti-CSF-1R antibody. Columns represent the
percentage of CSF-1R-positive cells within the bulk population analyzed (gated in order to exclude debris and cellular aggregates). Data represent the
mean (6 SEM) of 3 independent experiments. Asterisks indicate the HER2-overexpressing cell lines. One-way ANOVA among different subtypes
showed no differences.
doi:10.1371/journal.pone.0027450.g001
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To determine whether CSF-1R transduces proliferative signals in
breast cancer cells we chose two cell lines from different subtypes
(Figure 3). When basal MDAMB468 cells were exposed to exogenous
CSF-1, their proliferation increased by 40% and ERK1/2 and c-Jun
phosphorylation were markedly increased. In addition CSF-1
administration increased cell proliferation and ERK1/2 and c-Jun
phosphorylation of luminal SKBR3 cells. It is of note that this cell line
is characterized by a high basal ERK1/2 phosphorylation suggesting
an autocrine CSF-1/CSF-1R loop and/or activation of CSF-1R-
independent signaling pathways. The relevance of ERK1/2 in CSF-
1R signaling was highlighted by the fact that enhancement of ERK1/
2 phosphorylation upon CSF-1 treatment was found in 10 out of 17
breast cancer cell lines (Figure S2).
To further characterize CSF-1R involvement in breast cancer
cell proliferation we treated breast cancer cells (Figure 4) with
CSF-1R siRNA (Figure S1A and B). CSF-1R silencing in SKBR3
cells markedly impaired cell proliferation in the presence of ectopic
CSF-1 (Figure 4A), reduced the phosphorylation of ERK1/2 and
c-Jun as well as the expression of c-Myc, cyclin D1 (Figure 4B) and
several other cyclins (Figure 4C and Table 2).
To test whether an autocrine CSF-1/CSF-1R loop exists in
breast cancer cells (Figure 4D) we used a CSF-1-blocking
antiserum (Figure S1C) [49]. SKBR3 cells treated for 24 hours
with the CSF-1-blocking antiserum showed a 35% reduction in
proliferation when compared to the cells treated with the control
serum (pre-immune) (Figure 4D). In the same experiments, the
CSF-1-blocking antiserum markedly inhibited c-Jun phosphoryla-
tion and reduced cyclin D1 and c-Myc expression (Figure 4E).
This autocrine signaling sustained ERK1/2 activation in both
SKBR3 and MDAMB468 cells (Figure 4F) as demonstrated by the
fact that CSF-1 silencing partially impaired basal ERK1/2
phosphorylation. CSF-1 silencing was confirmed by Q-PCR (not
shown). The results shown in Figure 3 and 4 indicated the
involvement of ERK1/2 and its downstream targets (i.e. c-Jun,
cyclin D1 and c-Myc) in CSF-1-induced cell proliferation in breast
cancer cells.
The fact that CSF-1 promotes proliferation in breast cancer
cells prompted us to determine whether their growth is sensitive to
tyrosine kinase inhibitors used in the clinic. Imatinib (IM) is known
to inhibit CSF-1R activity [34]. We found, in keeping with
previous data [34], that 10 mM IM was necessary to prevent CSF-
1-induced CSF-1R phosphorylation in NIH/3T3-Fms cells
(Figure S1D). When 10 mM IM was given to SKBR3 and
MDAMB468 breast cancer cell lines for 48 hours in the presence
of CSF-1, cell number was markedly reduced, as determined by
crystal violet staining (Figure 5A). Further, IM was able to prevent
in part the activation of ERK1/2 induced by CSF-1 confirming
the involvement of ERK1/2 in the proliferative effect of CSF-1 in
breast cancer cells (Figure 5B). IM treatment alone did not
decrease ERK1/2 phosphorylation (not shown).
Discussion
Although the expression of CSF-1/CSF-1R has been previously
documented in breast cancer and shown to correlate with poor
prognosis, few studies have been performed to understand the role
of CSF-1R-dependent signaling in the proliferation of breast
cancer cells or other solid tumors [24,54,55]. In the present study
we found that: i) breast cancer cell lines consistently express CSF-1
and CSF-1R; ii) the CSF-1/CSF-1R pair sustains the proliferation
of breast cancer cell lines; iii) ERK1/2 is downstream CSF-1R in
proliferating breast cancer cells.
CSF-1R sustains breast cancer cells proliferation, as highlighted
in two cell lines of different molecular subtypes. Indeed, interfering
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Figure 2. In silico analysis of CSF1 and CSF1R genes expression in breast cancer datasets. CSF1 and CSF1R transcripts levels are shown for
breast cancer cell lines dataset (blue) from Neve et al. [41] and for two independent breast tumor datasets (red) from Minn et al. [43] and van de Vijver
et al. [44]. One-way ANOVA and the Bonferroni test did not show any statistical significant difference among the subtypes within the dataset.
doi:10.1371/journal.pone.0027450.g002
Figure 3. Effects of CSF-1 on the proliferation of breast cancer cells. MDAMB468 (A) or SKBR3 (B) cells were cultured in DMEM without serum
for 24 hours and then for additional 24 hours with DMEM with or without 25 ng/ml CSF-1. Cells were scored for (A) BrdU or (B) tritiated thymidine
uptake or lysed and protein subjected to immunoblotting with the indicated antibodies. (A) Values reported under the pictures are percentages (6
SEM) of BrdU-positive nuclei, normalized to total nuclei labeled by Hoechst 33258, from 5 independent experiments; **, Student’s t test: p,0.01. (B)
Data represent mean (6 SEM) of one out of 3 representative experiments; *, Student’s t test: p,0.05. Densitometric values of bands (normalized for
loading control) are reported as ratios between the CSF-1-treated and untreated value, set as 1.
doi:10.1371/journal.pone.0027450.g003
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with CSF-1/CSF-1R signaling, either by targeting the receptor or
by blocking the ligand binding, impacts on breast cancer cell
proliferation. This proliferation was induced either by ectopic
CSF-1, that mimic CSF-1 produced by fibroblasts and mono-
cytes/macrophages associated with the tumor, or autocrine CSF-
1. We found that CSF-1R activation sustained the expression of
cyclin D1 and c-Myc and activated c-Jun, which are established
CSF-1 downstream targets in other cell types [56]. Interestingly,
the expression of several cyclins was decreased following CSF-1R
silencing in SKBR3 cells, indicating that in these cells CSF-1R-
dependent signaling sustains the progression across different
phases of the cell cycle.
We also found that CSF-1R-induced proliferation involves
ERK1/2 activation in SKBR3 and MDAMB468 cells. Our data
are in line with previous studies in which breast cancer cell lines
expressing ectopic CSF-1R showed increased expression of cyclin
D1 as a consequence of ERK1/2 activation upon CSF-1
administration [57]. Our results therefore support the existence
of a proliferative pathway elicited by CSF-1/CSF-1R that acts
through ERK1/2 thereby inducing c-Jun activation as well as c-
myc and cyclin D1 expression. We also found that ERK5 [40,58]
is activated in a restricted number of cell lines following CSF-1
treatment (not shown). PI3K [59] was not activated by CSF-1 in
any of the cell lines tested. In this respect, it is to note, however,
that both ERK5 and PI3K pathways are often constitutively active
in breast cancer cells [58,60], possibly masking a response to CSF-
1.
Our data show that 16 cell lines among 17 tested express CSF-1
and CSF-1R, although at different levels. Moreover, gene
expression profiling datasets show that CSF1 and CSF1R
expression is a general feature of breast cancer cells. These
findings support the possibility to target CSF-1R signaling in a
Figure 4. Effects of CSF-1/CSF-1R inhibition on the proliferation and ERK1/2 phosphorylation of breast cancer cells. (A–C, F) SKBR3 or
(F) MDAMB468 cells were transfected with the indicated siRNA and incubated for 24 hours. (A) Cells were then serum-starved for a further 24 hours
and treated with 25 ng/ml CSF-1 for 24 hours, and tritiated thymidine uptake measured. Data represent mean (6 SEM) of one out of 3 representative
experiments; **, Student’s t test: p,0.01. (B, C, F) 72 hours post transfection cells were lysed and total protein or RNA extracted. (B, F) Protein lysates
were subjected to immunoblotting with the indicated antibodies. Densitometric values of bands (normalized for loading control) are reported as
ratios between the siCSF-1R and the siNT value, set as 1. (C) Q-PCR was performed for the indicated genes. Data were normalized against GAPDH.
siNT-treated samples (dark green) were chosen as calibrator over the siCSF1R-treated samples (light green). Data represent the mean (6 SEM) from
three independent experiments performed in triplicates. (D, E) SKBR3 cells were cultured in DMEM without serum for 24 hours and then for 24 hours
with 25 ng/ml CSF-1, pre-incubated for 1 hour with a 1:50 dilution of CSF-1-blocking anti-serum (I) or control pre-immune serum (PI). Cells were then
scored for BrdU uptake or lysed. (D) Values reported under the pictures, from 5 independent experiments, are percentages (6 SEM) of BrdU-positive
nuclei, normalized to total nuclei labeled by Hoechst 33258; ***, Student’s t test: p = 0.0004. (E) Protein lysates were subjected to immunoblotting
with the indicated antibodies. Densitometric values of bands (normalized for loading control) are reported as ratios between the I and the PI value,
set as 1.
doi:10.1371/journal.pone.0027450.g004
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large proportion of breast cancers, independently of their
molecular subtype. This is particularly relevant for tumors that
are classify as of the basal-like subtype. Triple-negative (ER-, PR-,
HER2-negative) breast cancers make up the majority of this
subgroup [41,61] and are generally unresponsive to standard
treatments, i.e. tamoxifen, aromatase inhibitors and herceptin.
Although triple-negative breast cancers can be treated with
chemotherapy, early relapse and metastasis is common and
therefore the need of potential targets for this tumors is of high
priority.
The data obtained from our experiments and in silico analysis
indicate that CSF-1R is not overexpressed (when compared to
human monocytes) nor amplified [62] and therefore support
previous reports [6] that the oncogenic potential of CSF-1R is due
to its co-expression with CSF-1. Furthermore, this conclusion is
further established by the fact that CSF-1R-dependent prolifera-
tion of SKBR3 cells is impaired when the CSF-1/CSF-1R
interaction is prevented. ERK1/2 is apparently involved in
autocrine-induced proliferation as silencing CSF-1 or CSF-1R
decreased ERK1/2 activation in both SKBR3 and MDAMB468.
Moreover, ERK1/2 was constitutively active in several cell lines
where CSF-1 exposure had a minor effect on the basal ERK1/2
phosphorylation. The low level or absent responsiveness to CSF-1
in these cell lines may be the consequence of autocrine CSF-1
production (as demonstrated for SKBR3) and/or of activation of
CSF-1R-independent signaling pathways.
IM is a tyrosine kinase inhibitor in use for the clinical
management of chronic myeloid leukemia and has been shown
to inhibit several different kinases, including CSF-1R. We found
that IM impairs the proliferation of breast cancer cell lines in the
presence of CSF-1. As IM targets kinases other than CSF-1R our
experiments do not prove that the effects shown are only due to
CSF-1R inhibition. However, they support the concept that
Table 2. Effect of CSF-1R silencing on the expression of cyclin
genes.
ID Gene name fold change p (t Student’s)
890 cyclin A2 0.438248 0.042839
891 cyclin B1 0.30756 0.030438
595 cyclin D1 0.488026 0.073304
894 cyclin D2 undetectable
896 cyclin D3 0.378628 0.047503
898 cyclin E1 0.352627 0.068412
9134 cyclin E2 0.387063 0.06905
900 cyclinE2 0.44102 0.02955134
901 cyclin G1 0.517056 0.034455
902 cyclin G2 11.70318 0.196287
10983 cyclin H 0.364232 0.009274
8812 cyclin I 0.268787 0.00119
905 cyclin K 0.333527 0.044601
890 cyclin T2 0.30201 0.00467
doi:10.1371/journal.pone.0027450.t002
Figure 5. Effects of imatinib on breast cancer cell survival and ERK1/2 phosphorylation in response to CSF-1. 24 hours serum deprived
SKBR3 or MDAMB468 cells were treated for 45 minutes with (light gray columns, right pictures) or without (dark gray columns, left pictures) 10 mM
imatinib (IM) and then with 25 ng/ml CSF-1 for (A) 48 hours or (B) 10 minutes. (A) Cells were scored for cell viability by crystal violet staining. Data
represent percentages (6 SEM) of crystal violet staining normalized for IM-untreated cells from 4 independent experiments; *, Student’s t test:
p,0.05. (B) Cells were lysed and protein lysates subjected to immunoblotting with the indicated antibodies. Densitometric values of bands
(normalized for loading control) are reported as ratios between treated and untreated value, set as 1.
doi:10.1371/journal.pone.0027450.g005
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targeting CSF-1R with tyrosine kinase inhibitors can effectively
block CSF-1-dependent growth stimulation. This is particularly
relevant when considering strategies to interfere with autocrine
CSF-1-dependent proliferation.
In conclusion, the evidence we provided for the expression and
functional role of the CSF-1/CSF-1R pair in breast cancer,
together with the established role of CSF-1/CSF-1R in breast
cancer motility and invasiveness [29–31], indicate that CSF-1R
targeting may be pursued therapeutically, irrespective of breast
cancer subtype, at either early or late stages of tumor progression.
Supporting Information
Figure S1 Settlement of CSF-1 or CSF-1R targeting
using NIH/3T3 cells expressing ectopic CSF-1R. (A)
NIH/3T3-Fms cells were transfected with the indicated siRNA.
Total protein lysates obtained at the indicated times were
subjected to immunoblotting with the indicated antibodies.
Densitometric values of bands (normalized for loading control)
are reported as ratios between the siCSF1R and the siNT value,
set as 1. 72 hours post-transfection cells were analyzed by flow
cytometry. Percentages of CSF-1R-positive cells are reported. (B)
NIH/3T3-Fms cells were transfected with the indicated siRNA
and incubated for 24 hours. Cells were then serum-starved for
further 24 hours and treated with (CSF-1) or without (2) 25 ng/
ml CSF-1 for 24 hours, and tritiated thymidine uptake measured.
Data represent mean (6 SEM) of one of 3 representative
experiments; ** and ***, Student’s t test: p,0.01, p,0.001,
respectively. (C) NIH/3T3-Fms cells were incubated with or
without 25 ng/ml CSF-1 for 10 minutes. Before cell treatment,
CSF-1 had been incubated for 1 hour at 37uC in the absence (2)
or the presence of a 1:50 dilution of a CSF-1-blocking anti-serum
(I) or pre-immune serum (PI). Total protein lysates were subjected
to immunoblotting with the indicated antibodies. Densitometric
values of bands (normalized for loading control) are reported as
ratios between the siCSF-1R and the correspondent siNT value,
set as 1. (D) NIH/3T3-Fms cells were cultured for 24 hours
without serum and then for 45 minutes with the indicated doses of
imatinib (IM) before treatment with or without 25 ng/ml CSF-1
for 10 minutes. Cells were then lysed and protein subjected to
immunoblotting with the indicated antibodies.
(TIF)
Figure S2 CSF-1 and CSF-1R gene copy number in
breast cancer cell lines and tumor samples. Data have
been collected from CGH experiments performed by others with
breast cancer cell lines (left) [41] or tumor samples (right) [47].
Whisker graphs represent median, 25- and 75- percentile, min and
max values.
(TIF)
Figure S3 CSF-1R signaling induces ERK1/2 phosphor-
ylation in breast cancer cell lines. Serum-deprived cells
(24 hours) were incubated with or without CSF-1 (25 ng/ml) for
10 minutes and lysed in RIPA buffer. Total protein lysates were
subjected to immunoblotting with the indicated antibodies. N3F:
NIH/3T3-Fms cells. Densitometric values of bands (normalized
for loading control) are reported as ratios between the CSF-1-
treated and the untreated value, set as 1. Threshold for activation
was arbitrary set at $1.2.
(TIF)
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